Neuroendocrine tumors of the lung : a five-year retrospective experience of Egyptian NCI (2010-2014)‎

Abstract EN

Background: The spectrum of lung neuroendocrine tumors (NETs) encompasses low grade typical carcinoid (TC), intermediate grade atypical carcionid (AC) and high grade, both large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC), with extreme differences in management and survival.

Objective: To study clinicopathologic and prognostic factors affecting survival of lung NETs.

Patients and methods: This is a retrospective study evaluating 35 patients with primary lung NETs treated at National Cancer Institute of Egypt (NCI-E) between January 2010 and December 2014.

Pathological diagnosis depended on definite morphology and positivity to at least one of the neuroendocrine markers by immunohistochemistry.

Results: The mean age of the patients was 53 ± 11.2 years with male predominance.

Performance status (PS) I was encountered in 48.6%.

SCLC was the prevalent histology in 68.6%, followed by LCNEC & TC in 20 & 11.4%, respectively.

Curative surgery was employed in 100 & 57% of TC & LCNEC patients, respectively.

Stage IV was anticipated in 87.5 & 43% of SCLC & LCNEC, respectively.

For the entire cohort, the median event-free survival (EFS) and overall survival (OS) were 8.0 and 13.7 months, respectively, whereas the 3- year EFS and OS were 17.8 & 20%, respectively.

SCLC patients showed significantly the worst OS compared to other NETs (p = 0.001).

Patients who presented with stage IV and PS > I demonstrated significantly shorter OS than those with locoregional and PS I (p = 0.00001 & p = 0.002, respectively).

Conclusions: SCLC subtype, stage IV and initial PS > I are poor prognostic factors for lung NETs associated with shorter survival.

This conclusion needs to be confirmed by larger studies